Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2a first-in-human intrathecal ION717 study in early prion disease
MOH_2024-01-04_013159Phase 2Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Dec 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ION717 in Prion Disease (PD) (3 arms), sponsored by Ionis Pharmaceuticals. Primary endpoint: Safety and tolerability of intrathecal ION717. Started Dec 2023; status: active, not recruiting.
02
Drugs
ION717
03
Conditions
Prion Disease (PD)
Beyond the preview
Go deeper on MOH_2024-01-04_013159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-04_013159.